Prevalence study of drugs and new psychoactive substances in hair of ketamine consumers using a methanolic direct extraction prior high-resolution mass spectrometry by Matey Cabañas, Jose Manuel et al.
Contents lists available at ScienceDirect 
Forensic Science International 
journal homepage: www.elsevier.com/locate/forsciint 
Prevalence study of drugs and new psychoactive substances in hair of 
ketamine consumers using a methanolic direct extraction prior to  
high-resolution mass spectrometry☆ 
J.M. Mateya,d,e,⁎,1, Gemma Montalvob,d,e,2,3, Carmen García-Ruizb,d,e,3,4, Félix Zapatac,5,  
Adrián López-Fernándezd,6, Maria A. Martíneza,e,7 
a Department of Chemistry and Drugs, National Institute of Toxicology and Forensic Sciences (INTCF), C/ José Echegaray no. 4, 28232 Las Rozas de Madrid, Madrid, 
Spain 
b Department of Analytical Chemistry, Physical Chemistry and Chemical Engineering; University of Alcalá, Ctra. Madrid-Barcelona km 33.600, 28871 Alcalá 
deHenares, Madrid, Spain 
c Department of Analytical Chemistry, University of Murcia, 30100 Murcia, Spain 
d University of Alcalá, Sciences Faculty, Department of Analytical Chemistry, Physical Chemistry and Chemical Engineering, CINQUIFOR research group, Ctra. 
Madrid–Barcelona km 33.600, 28871 Alcalá de Henares, Madrid, Spain 
e University of Alcalá, University Institute of Research in Police Sciences (IUICP), Colegio Máximo de Jesuitas, Calle Libreros 27, 28801 Alcalá de Henares, Madrid, 
Spain    
a r t i c l e  i n f o   
Article history: 
Received 17 May 2021 
Received in revised form 18 October 2021 
Accepted 22 October 2021 
Available online 28 October 2021  
Keywords: 
New psychoactive substance (NPS) 








a b s t r a c t   
Few studies have reported the prevalence or incidence about the consumption of new psychoactive sub-
stances (NPS). The hair analysis can be useful for this purpose. At the present, ketamine is the most con-
sumed arylcyclohexylamine associated to young consumers and polyconsumption profiles. For this reason, 
ketamine consumer cases become very interesting to provide information on NPS prevalence. In this work, 
ten former cases of the National Institute of Toxicology and Forensic Science (INTCF) of Madrid Department 
(INTCFM), all of them belonging to defendants accused of crimes against public health and who had been 
found positive to ketamine, were reassessed. At the first toxicological analysis of those hair samples, a 
positive consume in ketamine had been determined by gas chromatography coupled to mass spectrometry 
(GC-MS). In this work, the same hair samples were reanalyzed by high-resolution mass spectrometry ( 
UHPLC-HRMS/MS) using an incubation methanolic extraction combined with a single, simpler, non-se-
lective and direct sample pre-treatment. After corroborating the GC-MS results previously obtained for the 
same samples, the detection of additional NPS using this new methodology evidenced its benefits and 
opened the possibility to perform a NPS prevalence study. In brief, in those cases with a positive con-
sumption in ketamine, a polyconsumption of other drugs and NPS was found, including different 
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arylcyclohexylamines as deschloroketamine, 3-MeO-PCP and methoxetamine; and cathinones as methyl-
metcathinone and N-ethyl-pentylone. 
© 2021 The Authors. Published by Elsevier B.V. 
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1. Introduction 
Ketamine or 2-(2-chlorophenyl)-2-(methylamino)-cyclohex-
anone, is an arylcyclohexylamine synthesized by Calvin Stevens in 
1962, in the laboratory of Parke-Davis in Michigan [1,2] as an alter-
native analog of phencyclidine (PCP). 
It began to be used as an anesthetic and analgesic and cataloged 
as a dissociative drug. It has been used in general anesthesia in 
humans and veterinary medicine [1,2] for the last fifty years. 
As a curiosity, the dissociative effects of ketamine were described 
by the physician and scientist John C. Lylly after self-consumption, 
and he described its effects with the sentence “look across the 
border into other realities” [3]. Most likely, ketamine is illegally 
consumed due to its hallucinogenic and stimulants properties when 
consumed in high doses. 
This substance and its analogs must be strongly monitored in 
Drug Facilitated Crimes (DFC) because ketamine analogs do not 
present color or smell and possess effects related to sedation, an-
algesia, immobility and amnesia [4,5]. 
In the world, this substance has experienced an increment in 
non-medical uses, with a high prevalence in Asia [6,7]. In Europe it 
appeared in 1990 mixed in illicit preparations altogether with sti-
mulants (mainly MDMA) [8]. Because of the clinical use of ketamine, 
it was not included as a New Psychoactive Substance (NPS), but its 
combined use with NPS was established in the report on the risk 
assessment of ketamine in the framework of the joint action on new 
synthetic drugs of the European Monitoring Center for Drugs and 
Drugs Addiction (EMCDDA) [7]. Then, the International Narcotics 
Control Board (INCB), pursuant to resolutions 49/6, 50/3 and 57/10 of 
the Commission on Narcotic Drugs, called upon the governments to 
pay particular attention to the misuse and diversion of ketamine [7]. 
In Spain, ketamine was included as controlled substance in 2010 [9]. 
In toxicological and forensic cases, drugs are generally analyzed 
in different matrices (blood, urine, vitreous humor, hair, liver, gastric 
content, bile, kidney, lung, meconium, etc). The blood sample is the 
reference or sample of choice to quantify and interpret the con-
centrations of drugs and their metabolites of recent or acute in-
toxications. The hair samples present particularities and some 
additional advantages in different judicial investigations, such as a 
greater temporal window of detection, where the consumption in 
previous months or even years can be detected. In general, one 
centimeter of hair approximately reflects a period of one month 
(~1 cm/month) [10], where the proximal centimeters reflect the 
most recent consumption periods. The results are an average of the 
period analyzed, which is one of its limitations. The hair samples 
allow to investigate consumption patterns retrospectively and to 
know the polyconsumption pattern and prevalence of drugs and NPS 
consumed. 
The systematic screening procedures for NPS analysis in hair are 
limited, and, in fact, the pretreatment procedures traditionally em-
ployed in targeted methods for hair analysis usually take much time 
and effort [11–14]. At present, ketamine is the most consumed ar-
ylcyclohexylamine associated to young consumers and poly-
consumption profiles. There are around a hundred publications 
where its determination has been reported. These studies usually 
employ chromatographic separation techniques coupled to mass 
spectrometry [5,15–24]. Apart from the ketamine consumption, the 
research of other possible drugs or NPS is also very necessary from 
forensic cases with the aim of studying the prevalence of these 
substances in the population in a certain period. NPS are potentially 
dangerous and must be detected in forensic cases to reduce the 
damage in the society, as they may be sold on the Internet as “re-
search chemicals” or “legal highs”, accompanied by the indication 
that they are “not for human consumption”. Analytically, NPS and 
their metabolites need to be detected with a highly sensitive and 
selective analytical technique. Traditional combined techniques such 
as gas chromatography coupled to mass spectrometry (GC-MS) 
usually do not present enough sensitivity and selectivity in the for-
ensic analysis of NPS in hair. In addition, little information is known 
about NPS (mother drugs) and their metabolites in the human body. 
Generally, the mother drugs are present in the hair samples, which 
facilitates the identification, but the real forensic challenge comes 
when trying to detect the NPS metabolites in this matrix. These NPS 
and metabolites altogether will contribute to inform on the pre-
valence and detection of NPS in the population, or, at least, in sub-
jects involved in criminal cases analyzed by certain forensic 
institutions. In this work, some Spanish criminal cases involving 
ketamine consumers studied in the INTCFM from 2017 to 2018 were 
studied under the hypothesis that this type of consumers might have 
a poly-consumption profile involving other psychoactive sub-
stances [11]. 
As a consequence, this work aims to report the analytical ap-
proach followed in the INTCFM to confirm the presence of drugs of 
abuse (ketamine and other drugs) and the identification of other 
potential NPS in hair matrices from ten real cases related to criminal 
actions occurred in Spain involving ketamine consumption. Those 
cases had previously given positive results in ketamine by the rou-
tine method GC-MS [11]. To achieve this goal, the specific objectives 
pursued in this work were: (i) identification of arylcyclohexylamines 
and their metabolites present in the analyzed hair samples by 
UHPLC-HRMS/MS; and (ii) study of prevalence considering all the 
substances identified, with special focus on NPS and other halluci-
nogens detected, involved in the polyconsumption profile of keta-
mine consumers. Firstly, the study included the comparison of 
instrumentation and analytical performance of a high-resolution 
mass spectrometry (UHPLC-HRMS/MS) method to the traditional 
GC-MS method. Since the high-resolution method uses a single 
simpler, non-selective and faster sample pre-treatment, the first step 
of the study sought to corroborate the GC-MS results previously 
obtained for the same samples. In a second step, the detection of 
other NPS and metabolites evidenced the benefits of using this new 
extraction and chromatographic-spectrometric method. 
2. Experimental 
2.1. Standards and reagents 
LGC Promochem Cerilliant (Teddington, Middlesex, United 
Kingdom), Cayman Chemical (Ann Arbor, Michigan, USA) and 
Lipomed (Arlesheim, Switzerland) provided either pure solutions in 
methanol or acetonitrile at 1.0 mg/ mL or 1 mg (those which were 
solid) of the drug standards of several arylcyclohexylamines (keta-
mine, norketamine, phencyclidine (PCP), 3-methoxy-phencyclidine 
(3-MeO-PCP) and methoxetamine), two cathinones (N-ethylpenty-
lone (ephylone) and 4-methylmetcathinone (mephedrone)), LSD, 
dextromethorphan, and other drugs standards: amphetamine-like 
compounds (amphetamine, 3,4-methylendioxy-N-methyl-ampheta-
mine (MDMA or ecstasy), 3,4-methylendioxyamphetamine (MDA) 
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and 3,4-methylendioxy-N-ethyl-amphetamine (MDEA)). LGC 
Promochem Cerilliant also provided all the deuterated internal 
standards as 1.0 mg/ mL solutions in methanol: ketamine-d4, am-
phetamine-d5, MDMA-d5, methadone-d9, codeine-d3, morphine- 
d3, cocaine-d3 and benzoylecgonine-d3. All the stock solutions were 
stored at 4 ºC. 
All the reagent solutions used for UHPLC-HRMS/MS sample 
pretreatment were of analytical grade (> 99.9%). Sigma-Aldrich 
(Saint Louis, Missouri, USA) provided the derivatizing substances, 
that were pentafluoropropionic anhydride (PFPA) and 1,1,1,3,3,3- 
hexafluoro-2-propanol (HFIP). 
2.2. Hair samples 
The sampling of the hairs was performed following the sampling 
guidelines of the Society of Hair Testing (SoHT) [10]. Samples were: 
(i) blank hair of the same length (aliquot 0–3 cm), used to make the 
standard solutions for calibration and limit of detection (LOD) and 
limit of identification (LOI) from volunteers who had not taken any 
drugs or medication; and (ii) 10 hair samples collected from pre-
vious cases by the INTCFM. Table 1 summarizes the data of in-
dividuals and the characteristic of the lock of hair analyzed. All lock 
of hairs were subjected to a pretreatment stage. 
In this work, we reanalyze the same length of hair that was 
analyzed in the initial routine by GC-MS, for a better and comparable 
evaluation of these cases by the laboratory. 
3. Methods 
Beforehand, a pretreatment method used and evaluated by the 
INTCFM was employed for the study of the hair samples using a 
simpler and universal procedure extraction to prepare them for a 
screening analysis. 
3.1. Preanalytical hair sample treatment 
The steps followed to pretreat the hair samples for GC-MS are 
described in detail in Matey et al. [11]. Briefly, the GC-MS sample 
preparation consisted in (i) decontamination with dichloromethane; 
(ii) trituration of the hair and specific extractions, with basic di-
gestion (NaOH, 1 M) for amphetamines and ketamines; (iii) pur-
ification using liquid-liquid extraction (LLE) and solid-phase 
extraction (SPE); and (iv) derivatization using PFPA and ethyl 
acetate. 
Another extraction process was performed for specific analysis of 
cocaine and opioids by GC-MS with methanolic incubation (T=60ºC 
and t=18 h), and similar process of (i, iii and iv). It is done when it is 
necessary to analyze these substances. 
On the contrary, a single simpler sample treatment prior to the 
UHPLC-HRMS/MS analysis was made for all substances following the 
reference [25]. Briefly, it consisted in: (i) washing the hair samples 
twice with 5 mL of dichloromethane, and (ii) trituration of the hair 
and extraction of the analytes with methanol (methanolic incuba-
tion) for 18 h. Trituration was performed using a Precellys Tissue 
Homogenizer (from Bertin Instruments, Montigny-le-Bretonneux, 
France). All the internal standards were added prior to the metha-
nolic incubation. 
3.2. Instrumental methods 
The GC-MS methodology was the one traditionally employed to 
characterize drugs and their metabolites in suspects’ hair [11]. For 
UHPLC-HRMS/MS analysis of NPS, the pre-analytical extraction was 
a direct and non-selective (universal) extraction, adapted from 
Matey et al. [25,26]. The main analytical parameters for UHPLC- 
HRMS/MS analysis are summarized in Table 2. 
In the case of the UHPLC-HRMS/MS method [25,26], the ioniza-
tion mode was set up to electrospray ionization or H-ESI II in positive 
and negative ionization (switching), full scan ion monitoring using 
the same settings reported and described by A. G. Helfer et al.  
[27,28]. Phase A was added gradually to the Phase B, programmed as 
follows: 0–1.0 min 1% B, 1.0–10.0 min to 99% B, 10.0–11.5 min to 1% B 
and 11.5−13.5 min hold 1% B. The inclusion list for fragmentation was 
modified for different NPS and their corresponding metabolites 
molecular masses to be included and the full scan mode (FS). 
After studying the analytical performance of the method in terms 
of selectivity and LODs and LOIs, every chromatogram and frag-
mentation MS spectrum obtained was compared to all the chro-
matograms and spectra stored up in the INTCFM library, which 
contains more than 1550 standards in its database, with a specific 
high-resolution MS/MS spectra [27,28]. 
3.3. Data treatments: LOD, LOI and selectivity calculations 
To experimentally determine the limits of detection (LODs) and 
limits of identification (LOIs), decreasing concentrations (200, 50, 25, 
20, 15, 10, 5, 2 and 1 pg/mg) spiked in hair blank samples were 
prepared with the same process of extraction of real hair samples. 
The LOD was defined as the lowest concentration exhibiting a MS 
signal, which was produced by the accurate precursor ion [28] and a 
chromatographic signal at least of 3-times the background height in 
the chromatogram [29–32]. The LOI was defined by two different 
criteria: (i) the accurate precursor ion must be detectable (LOD) [28] 
and (ii) the underlying HRMS/MS spectrum must contain at least the 
two principal fragments of the reference library spectrum [28–32] 
corresponding with the lowest concentration of the analyte in the 
hair matrix. Table 1 
Summary of the data of individuals (n=10) and hair analyzed.         






(Y/N)   
M-1 Male -  4 4 Black No  
M-2 Male 25  3 3 Black No  
M-3 Male 32  5 5 Black No  
M-4 Male -  5 5 Brown No  
M-5 Female -  19 0–6a Yellow/ 
brown 
Yes  
M-6 Male -  22 0–6a - -  
M-7 Male 24  33 0–6a Black No  
M-8 Male 30  5 5 Black No  
M-9 Male 44  48 0–4a Black No  
M-10 Male 24  33 0–6a Black No  
a 0-X: The studied aliquot is from the hair root to the longest length of the analyzed 
locks of hair samples.  
Table 2 
Instrumentation and analytical parameters set for UHPLC-HRMS/MS. The extract was 
evaporated to dryness and reconstituted in 100 µL of methanol, from which only 1 µL 
was injected.    
Parameters UHPLC-HRMS/MS  
Stationary phase Phenylhexyl (100 mm×2.1 mm×2.6 µm). 
Mobile phase Phase A: ammonium formate 2 mM plus 0.1% formic 
acid (pH 3). 
Phase B: acetonitrile and methanol (50:50, v/v) plus 
0.1% formic acid and 1% of Phase A. 
Gradient (increasingly adding the Phase B in A). 
Detection Orbitrap Q Exactive Focus System 
Mode Full Scan Ion Monitoring (FSI) with Data-Dependent 
Acquisition (DDA) 
Injection 1 µL    
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The selectivity of the method was demonstrated by analyzing 10 
different blank of hair matrices in aliquots of three centimeters, 
which had not detected these substances or ≤LOD. 
4. Results and discussion 
In this section, the analytical approach for high resolution mass 
spectrometry analysis of ten forensic cases belonging to defendants 
accused of crimes against public health and positive in ketamine are 
presented. The results confirmed the presence of drugs of abuse 
(ketamine and other drugs) and different NPS in hair matrices. Three 
subsections are described: (i) a comparison of the detectability by 
the traditional GC-MS and the UHPLC-HRMS/MS methods em-
ployed; (ii) the identification of arylcyclohexylamines and their 
metabolites present in the analyzed hair samples; and finally (iii) an 
approach to prevalence study considering the substances identified 
in the ten cases studied, focusing on NPS and hallucinogens involved 
in the polyconsumption of ketamine consumers. 
4.1. Substance detectability in hair samples by UHPLC-HRMS/MS 
Firstly, all substances detected previously by GC-MS [11], where it is 
also realized a estimate of the LODs and LOIs of standard substances by 
UHPLC-HRMS/MS method. Table 3 shows the substances detected by 
UHPLC-HRMS/MS and their corresponding experimental LODs [28] and 
LOIs [28–32]., The drugs, NPS and metabolites detected were ketamine, 
norketamine, MeO-PCP, methoxetamine, N-ethylpentylone (ephylone), 
4-Methylmethcathinone (mephedrone or 4-MMC), 4-Bromo-2,5-di-
methoxyphenethylamine (2C-B), dextromethorphan, fentanyl, amphe-
tamine, methamphetamine, 3,4-methylendioxyamphetamine (MDA), 
3,4-methylendioxymethamphetamine (MDMA), 3,4-methylendiox-
yethylamphetamine (MDEA). Another potential NPSs that were not de-
tected were also analyzed just in case; such as different cathinones: 
4-Methylethcathinone (4-MEC), 4-Methyl-alpha-pyrrolidinbuthiophe-
none (4-Methyl-PPP), alpha-pyrrolidinbuthiophenone (alpha-PPP), 
alpha-pyrrolidinpenthiophenone (alpha-PVP), methylendioxypyrroli- 
dinovalerone (MDPV), Methylbenzodioxolylbutanamine (MBDB) 
Buphedrone, Pentedrone; Phenethylamines (PEAs): para-methox-
yamphetamine (PMA), para-methoxymethamphetamine (PMMA), 
25I-NBOME and 25C-NBOME; Synthetic cannabinoids (SC): JWH-018, 
JWH-073, JWH-122, JWH-210, AM-2201, UR-144 and XLR-11; Fentanyls: 
acetyl-fentanyl and cyclopropyl-fentanyl; Tryptamines: bufotenine and 
psylocine and Phenidates: ethylphenidate. 
For comparison purposes, the LOD of ketamine, norketamine and 
methoxetamine and the LOD and LOI of 2C-B calculated in previous 
studies [25,26] have been also included in Table 3. 
As expected, the calculated LODs and LOIs for the methanolic 
extraction followed by UHPLC-HRMS/MS methodology (Table 3) 
were lower than those values obtained for the conventional GC-MS 
methodology (preceded by a non-selective extraction). Lower LOD 
values imply better capability to detect smaller concentrations of 
analyte in the sample. In fact, ketamine had LOD values about two 
orders of magnitude lower with UHPLC-HRMS/MS than with GC-MS. 
Furthermore, different arylcyclohexylamines (deschloroketamine, 
methoxetamine [25] and MeO-PCP), cathinones (4-methylmet-
cathinone, N-ethylpentylone), hallucinogens 2C-B [26], DMT, LSD 
and opioids dextromethorphan were detected in these real samples 
using the UHPLC-HRMS/MS (preceded by a methanolic extraction). 
Unlike the simple conventional GC-MS interpretation, the inter-
pretation of all results from UHPLC-HRMS/MS requires some specific 
training. However, the higher detection capacity of UHPLC-HRMS/ 
MS may facilitate the detection of occasional or single consumptions 
by untargeted approaches, as for example in Drug-Facilitated Crimes 
(DFC). To the greater number of identifications produced by a higher 
detection capacity of the UHPLC-HRMS/MS method, it was added the 
advantage of using a single method of analysis requiring half of the 
amount of sample (20 mg) in comparison to the routine and more 
laborious GC-MS method (requiring 40 mg). 
4.2. Identification of arylcyclohexylamines and their metabolites in hair 
samples by UHPLC-HRMS/MS 
Currently, the identification of arylcyclohexylamine substances and 
their main metabolites in real hair samples is relevant to assess the 
type of polyconsumption in ketamine consumers [11]. As mentioned 
above, through UHPLC-HRMS/MS, different arylcyclohexylamines were 
detected in these real samples as well as different metabolites that 
were not detected by the GC-MS method formerly. Some information 
about the metabolism of methoxetamine is described by Matey et al.  
[31]. In this study, another arylcyclohexylamine-type metabolite was 
detected alongside deschloroketamine and was tentatively proposed as 
dehydrodeschloroketamine based on the main HRMS/MS ion frag-
ments present (see Supplementary material S1 and S2). 
The results obtained in this work regarding the prevalence of ar-
ylcyclohexylamines in hair samples was similar to those found in 
non-biological samples with the data available at the INTCFM [33] in a 
similar period of time. Non-biological material seized analyzed in 
2017 at the INTCFM (N=1991) contained arylcyclohexylamines (ACH) 
Table 3 
LODs and LOIs for new psychoactive substances (NPS) and some drugs and metabo-
lites [available standard drugs spiked into hair (see Section 3.3)] detected by UHPLC- 
HRMS/MS. Substances are grouped according to EMCDDA classification.      
Drug group detected 
(EMCDDA classification)[5] 







Arylcyclohexylamines Ketamine 2[25] 20 
Norketamine 2[25] 20 
Methoxetamine 5[25] 5 
MeO-PCP 5 200 
PCP 50 200 
Cathinones 4-MMC 20 50 
4-MEC 50 50 
Buphedrone 50 50 
Pentedrone 50 50 
N-ethylpentylone 5 25 
4-Methyl-PPP 5 15 
Alpha-PPP 15 25 
Alpha-PVP 5 20 
MDPV 5 10 
MBDB 10 15 
Phenethylamines (PEAs) Amphetaminea 25 50 
Methamphetaminea 20 20 
MDAa 50 50 
MDMAa 20 20 
MDEAa 10 10 
4F-Amphetamine 20 50 
PMA 10 25 
PMMA 10 25 
2C-B 10[26] 50[26] 
25I-NBOME 5 10 
Synthetic 
cannabinoids (SC) 
JWH-018 25 25 
JWH-073 10 50 
JWH-122 20 50 
JWH-210 5 10 
JWH-250 15 25 
AM-2201 5 50 
UR-144 20 50 
XLR-11 5 10 
Tryptamines LSDa 5 15 
Bufotenine 25 50 
Psylocine 50 50 
Opioids Dextromethorphana 2 10 
Fentanyla 10 50 
Acetyl-Fentanyl 20 50 
Cyclopropyl-Fentanyl 15 50 
Phenidates Ethylphenidate 5 20  
a Not classified as a New psychoactive substance, but it was also included due to its 
high consumption prevalence and high comorbidity associated.  
J.M. Matey, G. Montalvo, C. García-Ruiz et al. Forensic Science International 329 (2021) 111080 
4 
in 160 cases (8%), mainly ketamine (72.5% of the ACH cases, corre-
sponding to the 5.8% of total samples analyzed in 2017 in INTCFM), 
deschloroketamine (21.3%), 3-MeO-PCP (2.5%), methoxetamine (2.5%) 
and deschloro-N-ethyl-ketamine (1.2%) [34]. 
Interestingly, similar results were obtained in hair during the period 
under study (N=1189, 5.2% of positive cases to ketamine) by GC-MS [11] 
(see Fig. 1). When hair samples were reanalyzed by UHPLC-HRMS/MS, 
the arylcyclohexylamines detected were in the same order of frequency 
than non-biological samples. Ketamine was detected in all the selected 
cases (N=10), deschloroketamine (2), methoxetamine (1) and 3-MeO- 
PCP (1), although the deschloro-N-ethyl-ketamine was not detected. 
4.3. Substances identified in the selected forensic cases: drug prevalence 
Results reported in [11] and our results showed in the previous 
section demonstrate the actual advantages for the detection of ar-
ylcyclohexylamines and their metabolites using the high-resolution 
technique of UHPLC-HRMS/MS. The additional information facilitates a 
prevalence approach focused on the drug abuse of NPS in ketamine 
consumers. The study of prevalence of NPS is interesting in hair ma-
trices for several reasons: (i) most drugs are mainly not metabolized, 
and (ii) the accumulative consumptions during large periods can be 
detected along the hair, as reported by Fabresse et al. [13]. 
Therefore, the identification of NPS, their main metabolites and 
other drugs present in the hair samples of the ten cases studied con-
firmed, again, the polyconsumption profile of ketamine users. In the 
cases analyzed (N=10), again all drugs of abuse previously detected by 
the routine method by GC-MS, as well as new NPS that had not been 
previously tested using GC-MS, such as mephedrone, N-ethylpentylone 
(ephylone), and other three arylcyclohexylamines (methoxetamine, 
deschloroketamine and methoxy-PCP), they all were detected by 
UHPLC-HRMS/MS. These NPS were grouped as different arylcyclohex-
ylamines and, besides them, two cathinones (methylmetcathinone 
(MMC) and N-ethylpentylone (ephylone)), and another interesting drug 
group such as hallucinogens, where three types of substances were 
detected: 4-bromo-2,5 -dimethoxyphenylethylamine (2C-B), trypta-
mines and dextromethorphan, which in high dose is known to have 
some hallucinogen effects [34]. These results are gathered in Fig. 2. 
NPS methoxetamine, deschloroketamine and MeO-PCP were 
classified as arylcyclohexylamines (see Fig. 2, in red, four cases). 
Methylmetcathinone and ephylone were classified as cathinones 
(see Fig. 2, in blue, two cases). It must be highlighted that some of 
the hallucinogens present (Fig. 2 in green, six cases in total) may be 
also cataloged as NPS. LSD and DMT were detected and classified as 
tryptamines (two cases). Other hallucinogens are 2C-B (one case) 
and dextromethorphan (three cases), whose hallucinogenic effects 
are well-known when consumed in high doses [34]. 
In addition, other substances were detected: cocaine, benzoy-
lecgonine, ethylbenzoylecgonine, norcocaine, tramadol, venlafaxine, 
gabapentin, methylphenidate, haloperidol, aripiprazole, sildenafil, 
quetiapine, carbamazepine, olanzapine, levetiracetam, bromazepam, 
nordiazepam, diazepam, alprazolam and clonazepam. All this wide 
profile of substances and metabolites reflects a high polyconsump-
tion behavior among ketamine consumers. 
In a previous study of criminal forensic cases [11] where more 
than 1189 hair cases were analyzed by GC-MS, more than 5.2% had 
already been positive for ketamine. The consumer type was a young 
profile (median=29 years), polyconsumer, and probably for recrea-
tional experiences. The supplier is most likely in the darknet (illicit 
market on the Internet) [35]. 
The UHPLC-HRMS/MS method has proven better detectability 
than the traditional GC-MS method used in the INTCFM, obtaining 
lower limits of detection, up to two orders of magnitude lower. 
5. Conclusions 
Sample preparation by methanolic incubation is used in the la-
boratory of INTCFM prior to GC-MS only for specific target analytes. 
The extraction was improved, simplified and extended to every 
analyte obtaining a non-selective and universal process that requires 
less amount of sample (20 mg instead of 40 mg) for the subsequent 
analysis of Drugs, NPS and metabolites by high resolution mass 
spectrometric methods. 
Regarding the prevalence or incidence of NPS considering ten 
forensic cases belonging to defendants accused of crimes against 
public health and with a positive consumption in ketamine, a 
polyconsumption of other drugs (hallucinogens and NPS) was also 
confirmed by. The concomitant consumption of classical drugs of 
abuse, stimulants and other drugs used for therapeutic or recreative 
consumption, reinforces the idea of the high polyconsumption be-
havior of consumers of ketamine. 
Fig. 1. Prevalence of ketamine in a similar period in hair and non-biological samples in the INTCFM. Hair samples were analyzed by GC-MS in the routine method [11] with n=62 
positive cases for ketamine of a total seized analysis of N=1189 in 2017–2018 (15 months). Non-biological samples, were collected from our public memory of INTCF in 2017 with 
n=116 positive cases for ketamine in a total analyzed of N=1991 [33]. 
Fig. 2. Highlight about prevalence of some drugs detected in the forensic cases (N=10) 
involving a positive consumption of ketamine. X-axis gives the frequency of the re-
ferred drugs. (For interpretation of the references to color in this figure legend, the 
reader is referred to the web version of this article.). 
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